Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above 50 Day Moving Average – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $11.36 and traded as high as $12.73. Astellas Pharma shares last traded at $12.73, with a volume of 59,907 shares.

Wall Street Analyst Weigh In

ALPMY has been the topic of several research analyst reports. Sanford C. Bernstein cut Astellas Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 2nd. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Astellas Pharma presently has an average rating of “Hold”.

Astellas Pharma Trading Down 0.5%

The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20. The company has a 50-day simple moving average of $11.36 and a two-hundred day simple moving average of $10.68.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.10. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.21%. The company had revenue of $3.45 billion during the quarter, compared to the consensus estimate of $3.14 billion. Sell-side analysts anticipate that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.